Skip to main content

Table 1 Results from the pre-specified multivariate Cox model

From: A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

Prognostic factors Hazard ratio (95.34% CI) p-value
Treatment: FOLFIRI-aflibercept versus FOLFIRI-placebo 0.817 [0.713; 0.936] 0.0032
ECOG PS: 1 vs 0 1.683 [1.465; 1.935] < 0.0001
ECOG PS: 2 vs 0 3.625 [2.395; 5.486] <0.0001
Prior bevacizumab: yes vs no 1.165 [1.003; 1.353] 0.0425
Age (years): ≥65 vs <65 1.179 [1.020; 1.363] 0.0233
Prior hypertension: yes vs no 0.785 [0.682; 0.904] 0.0007
Number of metastatic organs involved as per IRC: >1 vs (0–1) 1.446 [1.258; 1.663] < 0.0001
  1. ECOG, European Cooperative Oncology Group; FOLFIRI, 5-fluorouracil–leucovorin–irinotecan; IRC, independent review committee; PS, performance status.